ArticleAddiction (Abingdon, England)2026
Emergency department presentations, hospitalisations and police seizure data related to gamma-hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024.
Article in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Quantitative Analysis of Street-Level Drugs Seized in New South Wales, Australia: Purity, Dose and Adulterants.Drug and alcohol review · 2026Article
- Toxicological and Clinical Characteristics of Fatal Cases in the Emerging Drugs Network of Australia-Victoria (EDNAV) Clinical Registry 2020-2025.Emergency medicine Australasia : EMA · 2026Observational
- 'A fine line between euphoria and death': a qualitative study exploring gamma-hydroxybutyrate (GHB) use among people who identify as heterosexual living in Australia.Harm reduction journal · 2026Article
- Emergency department presentations, hospitalisations and police seizure data related to gamma-hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024.Addiction (Abingdon, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsGamma-hydroxybutyrate (GHB) is an endogenous neurochemical and illicit synthetic drug. Its precursors, gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD), are often used as substitutes. We aimed to describe GHB-related harms in New South Wales (NSW), Australia. DESIGN, SETTING AND CASES: Descriptive epidemiological study of data from three administrative datasets: emergency department (ED) presentations from 88 hospitals (1 July 2015 to 31 January 2024 - the latest available), admitted patient data from all NSW hospitals (1 July 2015 to 30 June 2023) and a subset of NSW Police Force seizure data. Note: analysis was not undertaken, data are presented descriptively. MEASUREMENTS: ED presentations and hospitalisations were analysed for GHB-related presentations and admissions including severity of presentation, intubation and intensive care. NSW Police Force seizure data were examined for all analytically confirmed samples of GHB, GBL and 1,4-BD to assess trends over time.
findingsOver the study period, there were 9612 GHB-related ED presentations. Between July 2023 and January 2024, this was 101 per 100 000 unplanned presentations, relative to the previous full-year peak of 73.7 per 100 000 in 2022-2023 and the 2015-2016 rate of 24.9 per 100 000. The majority (56.1%) were assessed as Australian Triage Category 1 or 2, indicating the highest level of need. ED presentations in regional or remote areas accounted for 13.8% of all presentations in the most recent data, relative to 3.4% at the start of the study period. Hospitalisations totalled 6420 episodes, peaking at 19.6 per 100 000 population in 2020-2021. Nearly one in five patients required intubation, and a similar proportion required admission to intensive care. There was a trend of women accounting for a larger proportion of ED presentations and hospitalisations over time. GHB accounted for 0.1% of all police seizures analysed, and showed a shift from GBL to 1,4-BD dominance from 2022 onwards.
conclusionsGamma-hydroxybutyrate-related emergency department presentations and hospitalisations in New South Wales, Australia, appear to have increased over the period from 2015 to 2024, which can support public health campaigns to reduce gamma-hydroxybutyrate-related harms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.